Table 2.
Tumor response in the total and subgroups according to mRECIST and RECIST 1.1.
| mRECIST | RECIST | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | BCLC B | BCLC C | Total | BCLC B | BCLC C | |||||||||||||
| TO (n = 64) | TA (n = 32) | p | TO (n = 32) | TA (n = 16) | p | TO (n = 32) | TA (n = 16) | p | TO (n = 64) | TA (n = 32) | p | TO (n = 32) | TA (n = 16) | p | TO (n = 32) | TA (n = 16) | p | |
| CR | 0 (0) | 3 (9.4%) | 0 (0) | 1 (6.3%) | 0 (0) | 2 (12.5%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
| PR | 30 (46.9%) | 18 (56.2%) | 17 (53.1%) | 12 (75.0%) | 13 (40.6%) | 6 (37.5%) | 10 (15.6%) | 15 (46.9%) | 6 (18.8%) | 9 (56.3%) | 4 (12.5%) | 6 (37.5%) | ||||||
| SD | 25 (39.0%) | 8 (25.0%) | 11 (34.4%) | 2 (12.4%) | 14 (43.8%) | 6 (37.5%) | 45 (70.3%) | 14 (43.7%) | 22 (68.7%) | 6 (37.5%) | 23 (71.9%) | 8 (50.0%) | ||||||
| PD | 9 (14.1%) | 3 (9.4%) | 4 (12.5%) | 1 (6.3%) | 5 (15.6%) | 2 (12.5%) | 9 (14.1%) | 3 (9.4%) | 4 (12.5%) | 1 (6.2%) | 5 (15.6%) | 2 (125%) | ||||||
| ORR | 30 (46.9%) | 21 (65.6%) | 0.064 | 17 (53.1%) | 13 (81.3%) | 0.055 | 13 (40.6%) | 8 (50.0%) | 0.378 | 10 (15.6%) | 15 (46.9%) | 0.001 | 6 (18,8%) | 9 (56.3%) | 0.011 | 4 (12.5%) | 6 (37.5%) | 0.054 |
| DCR | 55 (85.9%) | 29 (90.6%) | 0.382 | 28 (87.5%) | 15 (93.8%) | 0.454 | 27 (84.4%) | 14 (87.5%) | 0.571 | 55 (85.9%) | 29 (90.6%) | 0.382 | 28 (87.5%) | 15 (93.8%) | 0.454 | 27 (84.4%) | 14 (87.5%) | 0.571 |
mRECIST, modified Response Evaluation Criteria in Solid Tumors; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; TO, TACE only; TA, TACE combined with anlotinib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.